References
- Dreger P, Dohner H, Ritgen M, . Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. Blood 2010;116:2438–2447.
- Jensen MC, Popplewell L, Cooper LJ, . Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. Biol Blood Marrow Transplant 2010;16:1245–1256.
- Brentjens RJ, Riviere I, Park JH, . Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 2011;118:4817–4828.
- Savoldo B, Ramos CA, Liu E, . CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest 2011;121:1822–1826.
- Kalos M, Levine BL, Porter DL, . T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011;3:95ra73.
- Kochenderfer JN, Dudley ME, Feldman SA, . B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 2012;119:2709–2720.
- Till BG, Jensen MC, Wang J, . CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood 2012;119:3940–3950.
- Pegram HJ, Lee JC, Hayman EG, . Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood 2012;119:4133–4141.
- Singh H, Figliola MJ, Dawson MJ, . Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies. Cancer Res 2011;71: 3516–3527.
- Hoyos V, Savoldo B, Quintarelli C, . Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia 2010;24: 1160–1170.
- Xu X-J, Zhao H-Z, Tang Y-M. Efficacy and safety of adoptive immunotherapy using anti-CD19 chimeric antigen receptor transduced T cells: a systematic review of phase I clinical trials. Leuk Lymphoma 2012;53:XXX–XXX.
- Kochenderfer JN, Wilson WH, Janik JE, . Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 2010;116:4099–4102.
- Singh H, Manuri PR, Olivares S, . Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system. Cancer Res 2008;68:2961–2971.
- Provasi E, Genovese P, Lombardo A, . Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer. Nat Med 2012;18:807–815.
- Fukuda T, Chen L, Endo T, . Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a. Proc Natl Acad Sci USA 2008;105: 3047–3052.